Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lundbeck has decided to investigate Lu AA34893 for the treatment of bipolar disorder. The decision is based on positive pre-clinical results as well as positive conclusion of the Phase I trials in healthy individuals.
Subscribe to our email newsletter
The first patients in a 600-patient Phase II study have been enrolled. The study will investigate the effects of Lu AA34893 on the depressive episodes in bipolar disorder and its potential to prevent occurrence of mania. Lu AA34893 was selected as a development candidate based on its convincing effect in preclinical animal models suggesting a potential to improve the treatment of mood disorder.
Anders Gersel Pedersen, senior vice president, head of development at Lundbeck, said: “This study marks the first entry into bipolar disorder for Lundbeck and if successful, Lu AA34893 will provide a completely new approach to treat the needs of patients with bipolar disorder.”